Resveratrol: Ready for prime time?

Journal of Molecular and Cellular Cardiology

Volumn 42, Issue 3, 2007, Pages 484-486

  Dawn, Buddhadeb ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; PRAVASTATIN; RESVERATROL;

ANGIOGENESIS; APOPTOSIS; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; DOSE RESPONSE; DRUG ACTIVATION; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; EDITORIAL; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RED WINE;

ANIMALS; HEART; HUMANS; HYPERCHOLESTEROLEMIA; STILBENES;

EID: 33847774731     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.11.014     Document Type: Editorial

References (24)

1. Bhat K.P.L., Kosmeder II J.W., and Pezzuto J.M. Biological effects of resveratrol. Antioxid. Redox Signal. 3 (2001) 1041-1064
2. Baur J.A., and Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev., Drug Discov. 5 (2006) 493-506
3. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'?. Eur. J. Endocrinol. 138 (1998) 619-620
4. Ray P.S., Maulik G., Cordis G.A., Bertelli A.A., Bertelli A., and Das D.K. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic. Biol. Med. 27 (1999) 160-169
5. Kaga S., Zhan L., Matsumoto M., and Maulik N. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J. Mol. Cell. Cardiol. 39 (2005) 813-822
6. Sato M., Maulik N., and Das D.K. Cardioprotection with alcohol: role of both alcohol and polyphenolic antioxidants. Ann. N. Y. Acad. Sci. 957 (2002) 122-135
7. Hattori R., Otani H., Maulik N., and Das D.K. Pharmacological preconditioning with resveratrol: role of nitric oxide. Am. J. Physiol.: Heart Circ. Physiol. 282 (2002) H1988-H1995
8. Imamura G., Bertelli A.A., Bertelli A., Otani H., Maulik N., and Das D.K. Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice. Am. J. Physiol.: Heart Circ. Physiol. 282 (2002) H1996-H2003
9. Das S., Cordis G.A., Maulik N., and Das D.K. Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. Am. J. Physiol.: Heart Circ. Physiol. 288 (2005) H328-H335
10. Das S., Tosaki A., Bagchi D., Maulik N., and Das D.K. Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling. J. Pharmacol. Exp. Ther. 317 (2006) 980-988
11. Fukuda S., Kaga S., Zhan L., Bagchi D., Das D.K., Bertelli A., et al. Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem. Biophys. 44 (2006) 43-49
12. Penumathsa S.V., Thirunavukkarasu M., Koneru S., Juhasz B., Zhan L., Pant R., et al. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J. Mol. Cell. Cardiol. 42 (2007) 508-516 10.1016/j.yjmcc.2006.10.018
13. Liao J.K., and Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 89-118
14. Jones S.P., and Lefer D.J. Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. Acta Physiol. Scand. 173 (2001) 139-143
15. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6 (2000) 1004-1010
16. Verma S., Rao V., Weisel R.D., Li S.H., Fedak P.W., Miriuka S., et al. Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells. J. Surg. Res. 119 (2004) 66-71
17. Urbich C., Dernbach E., Zeiher A.M., and Dimmeler S. Double-edged role of statins in angiogenesis signaling. Circ. Res. 90 (2002) 737-744
18. Ito M., Adachi T., Pimentel D.R., Ido Y., and Colucci W.S. Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation 110 (2004) 412-418
19. Demyanets S., Kaun C., Pfaffenberger S., Hohensinner P.J., Rega G., Pammer J., et al. Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro. Biochem. Pharmacol. 71 (2006) 1324-1330
20. Clement M.V., Hirpara J.L., Chawdhury S.H., and Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 92 (1998) 996-1002
21. Hsieh T.C., and Wu J.M. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp. Cell Res. 249 (1999) 109-115
22. Weis M., Heeschen C., Glassford A.J., and Cooke J.P. Statins have biphasic effects on angiogenesis. Circulation 105 (2002) 739-745
23. Tseng S.H., Lin S.M., Chen J.C., Su Y.H., Huang H.Y., Chen C.K., et al. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin. Cancer Res. 10 (2004) 2190-2202
24. Igura K., Ohta T., Kuroda Y., and Kaji K. Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett. 171 (2001) 11-16